Abhinav Rajendra Prabhu, Bennett Catherine M, Anjana Ranjit Mohan, Pramodkumar Thyparambil Aravindakshan, Senthilmurugan Mullainathan, Livingston Patricia M, Pradeepa Rajendra, Mohan Viswanathan, Williams Joanne
School of Health and Social Development, Institute for Health Transformation, Faculty of Health, Deakin University, Geelong, Australia.
Madras Diabetes Research Foundation and Dr Mohan's Diabetes Specialities Centre, No: 4, Conran Smith Road, Gopalapuram, Chennai, 600086 India.
J Maxillofac Oral Surg. 2025 Apr;24(2):432-440. doi: 10.1007/s12663-024-02212-6. Epub 2024 May 24.
To evaluate the expression of salivary and serum Insulin-like growth factor-1 (IGF-1) and Insulin-like growth factor binding protein-3 (IGFBP-3) in individuals with and without diabetes and oral cancer.
The cross-sectional study included 4 groups ( = 12/group). Group I consisted of healthy individuals (controls), Group II individuals with type 2 diabetes (T2D) without oral cancer, Group III individuals had only oral cancer and Group IV individuals had oral cancer and T2D. Demographic characteristics and biochemical values were recorded. Salivary and serum IGF-1 and IGFBP-3 were measured using a quantitative sandwich ELISA technique.
Serum IGF-1 levels [Median (Inter-quartile range)] were highest among the control group [255 (135) ng/ml], followed by only T2D group [210 (147) ng/ml], oral cancer with T2D group [149 (45) ng/ml] and finally the oral cancer group [143 (81) ng/ml, p for trend = 0.004]. Salivary IGF-1 values were significantly higher in both the groups with T2D [T2D:0.42 (0.20) ng/ml; oral cancer with T2D: 0.40 (0.21) ng/ml] when compared to those with only oral cancer [0.27 (0.06) ng/ml] and controls: 0.17 (0.17) ng/ml], p for trend = 0.007]. Serum IGFBP-3 was significantly higher in both the oral cancer groups [without T2D: 13.1(10.4) ng/ml; with T2D: 14.9 (8.5) ng/ml] compared to only T2D [0.27 (0.06) ng/ml] and controls [8.7 (3.5) ng/ml, for trend = 0.001]. However, no significant trend was observed in salivary IGFBP-3 levels.
IGF-1 and IGFBP-3 are not reliable biomarkers for oral cancer screening or risk prediction. Further research is needed to confirm if they can be used as prognostic tools during treatment.
评估有或无糖尿病及口腔癌个体唾液和血清中胰岛素样生长因子-1（IGF-1）及胰岛素样生长因子结合蛋白-3（IGFBP-3）的表达情况。
横断面研究纳入4组（每组n = 12）。第一组为健康个体（对照组），第二组为无口腔癌的2型糖尿病（T2D）个体，第三组为仅患有口腔癌的个体，第四组为患有口腔癌且患有T2D的个体。记录人口统计学特征和生化值。采用定量夹心酶联免疫吸附测定（ELISA）技术检测唾液和血清中的IGF-1及IGFBP-3。
血清IGF-1水平[中位数（四分位间距）]在对照组中最高[255（135）ng/ml]，其次是仅患有T2D的组[210（147）ng/ml]、患有口腔癌且患有T2D的组[149（45）ng/ml]，最后是口腔癌组[143（81）ng/ml，趋势p = 0.004]。与仅患有口腔癌的组[0.27（0.06）ng/ml]和对照组[0.17（0.
